As medical director for oncology services, Monica Mead specializes in hematologic malignancies with over a decade of clinical and research expertise in CAR-T cell therapy. Her work spans all clinical trial phases, including leadership in trials advancing innovative CAR-T cell therapies. Monica has contributed to evaluating CAR-T cell outcomes in real-world settings, optimizing care strategies, and identifying predictive risk factors through multicenter analyses. She has also played a key role in developing outpatient CAR-T cell administration protocols, enhancing accessibility and patient care. Monica’s efforts continue to shape oncology advancements, bringing cutting-edge therapies to patients.